News

Psychedelic Stock News: Origin Therapeutics (CSE: ORIG Proposed) Launches to Fund Emerging Psychedelics Companies

Vancouver, B.C. – July 21, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”), an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.

The Company is focused on providing retail investors with exposure to a portfolio of diverse private companies in the psychedelics sector that they would otherwise be unable to participate in the growth of.

“There is a tremendous amount of innovation taking place in the psychedelics sector,” said Origin Therapeutics CEO Alexander Somjen. “Investors want to get in on it – but for many, it is only possible to access companies that are already publicly traded, which means that a lot of that initial opportunity to participate in the earliest stages of growth has passed.”

Origin Therapeutics plans to invest in a diverse range of psychedelic companies that encompass different areas of growth in the industry. This could include early-stage drug development companies, clinics, and other ancillary companies that help to push the industry forward, such as those companies focused on education, marketing, and building awareness around the psychedelics industry.

“We believe this industry has the potential to revolutionize a crucial area of healthcare,” Somjen said. “There is an increased interest in mental health, and psychedelics are a promising untapped resource that we have just scratched the surface of.”

According to a 2017 report from Our World in Data, around one in seven people globally (11-18%) have one or more mental health or substance use disorders. Data Bridge Market Research estimates that the psychedelics industry will grow to $6.9 billion by 2027.

About Origin Therapeutics

Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow Us on StockTwits

Buy a cannabis guest post on Investorideas.com

image

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News